Brian R. Mueller net worth and biography

Brian Mueller Biography and Net Worth

Brian R. Mueller joined BioMarin in December 2002 and currently serves as Executive Vice President, Chief Financial Officer. In his role, he is responsible for managing all Finance and Information Management teams. Prior to this, he served as Senior Vice President, Finance and Chief Accounting Officer and as Group Vice President, Corporate Controller.

Before joining BioMarin, Mr. Mueller worked for KPMG as a senior manager in the firm’s audit practice. Mr. Mueller joined KPMG after Arthur Andersen LLP ceased operations in June 2002, prior to which he spent seven years with Arthur Andersen LLP in the firm’s audit and business advisory services practice.

From June 2014 to May 2020, Mr. Mueller was a member of the board of directors of Anthera Pharmaceuticals, Inc., a previously public biopharmaceutical company, where he also served as Chairman of the Audit Committee. Mr. Mueller received a B.S. in Accountancy from Northern Illinois University in DeKalb, Illinois, and is a member of the American Institute of Certified Public Accountants.

What is Brian R. Mueller's net worth?

The estimated net worth of Brian R. Mueller is at least $2.61 million as of July 8th, 2022. Mr. Mueller owns 30,726 shares of BioMarin Pharmaceutical stock worth more than $2,613,246 as of September 29th. This net worth estimate does not reflect any other assets that Mr. Mueller may own. Additionally, Mr. Mueller receives a salary of $1,130,000.00 as CFO at BioMarin Pharmaceutical. Learn More about Brian R. Mueller's net worth.

How old is Brian R. Mueller?

Mr. Mueller is currently 48 years old. There are 5 older executives and no younger executives at BioMarin Pharmaceutical. The oldest executive at BioMarin Pharmaceutical is Mr. Jean-Jacques Bienaime M.B.A., MBA, Chairman & CEO, who is 69 years old. Learn More on Brian R. Mueller's age.

What is Brian R. Mueller's salary?

As the CFO of BioMarin Pharmaceutical Inc., Mr. Mueller earned a total compensation package of $4,699,165.00 in 2021. Mr. Mueller earned a salary of $600,000.00, stock awards of $2,773,957.00, options awards of $793,742.00, non-equity compensation of $511,500.00, and other compensation of $19,966.00.There are 4 executives that earn more than Mr. Mueller. The highest earning executive at BioMarin Pharmaceutical is Mr. Jean-Jacques Bienaime M.B.A., MBA, Chairman & CEO, who commands a salary of $3,670,000.00 per year. Learn More on Brian R. Mueller's salary.

How do I contact Brian R. Mueller?

The corporate mailing address for Mr. Mueller and other BioMarin Pharmaceutical executives is 770 Lindaro Street, San Rafael CA, 94901. BioMarin Pharmaceutical can also be reached via phone at (415) 506-6700 and via email at [email protected] Learn More on Brian R. Mueller's contact information.

Has Brian R. Mueller been buying or selling shares of BioMarin Pharmaceutical?

Within the last three months, Brian R. Mueller has sold $656,661.50 of BioMarin Pharmaceutical stock. Most recently, Brian Mueller sold 7,337 shares of the business's stock in a transaction on Friday, July 8th. The shares were sold at an average price of $89.50, for a transaction totalling $656,661.50. Following the completion of the sale, the chief financial officer now directly owns 30,726 shares of the company's stock, valued at $2,749,977. Learn More on Brian R. Mueller's trading history.

Who are BioMarin Pharmaceutical's active insiders?

BioMarin Pharmaceutical's insider roster includes Jeffrey Ajer (EVP), Jean Bienaime (CEO), George Davis (EVP), Willard Dere (Director), Henry Fuchs (Insider), Michael Grey (Director), Charles Guyer (EVP), V. Lawlis (Director), Richard Meier (Director), Brian Mueller (CFO), David Pyott (Director), and Dennis Slamon (Director). Learn More on BioMarin Pharmaceutical's active insiders.

Are insiders buying or selling shares of BioMarin Pharmaceutical?

In the last twelve months, insiders at the biotechnology company sold shares 26 times. They sold a total of 183,464 shares worth more than $15,403,131.65. The most recent insider tranaction occured on August, 15th when CEO Jean Jacques Bienaime sold 3,000 shares worth more than $285,630.00. Insiders at BioMarin Pharmaceutical own 1.8 % of the company. Learn More about insider trades at BioMarin Pharmaceutical.

Information on this page was last updated on 8/15/2022.

Brian R. Mueller Insider Trading History at BioMarin Pharmaceutical

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/8/2022Sell7,337$89.50$656,661.5030,726View SEC Filing Icon  
5/4/2022Sell11,800$84.50$997,100.0038,639View SEC Filing Icon  
5/7/2021Sell6,709$79.50$533,365.5031,357View SEC Filing Icon  
4/1/2021Sell5,692$76.30$434,299.6031,016View SEC Filing Icon  
4/5/2019Sell2,953$94.00$277,582.0013,660View SEC Filing Icon  
8/7/2018Sell2,500$104.50$261,250.0014,093View SEC Filing Icon  
6/22/2018Sell3,145$99.50$312,927.5012,375View SEC Filing Icon  
6/15/2018Sell2,021$94.50$190,984.5013,029View SEC Filing Icon  
5/10/2018Sell2,450$89.50$219,275.0017,846View SEC Filing Icon  
6/22/2017Sell2,671$100.00$267,100.0015,556View SEC Filing Icon  
5/8/2017Sell7,482$91.87$687,371.3418,350View SEC Filing Icon  
8/1/2016Sell287$100.00$28,700.0014,260View SEC Filing Icon  
12/2/2014Sell11,950$90.91$1,086,374.50View SEC Filing Icon  
5/14/2013Sell4,947$70.35$348,021.45View SEC Filing Icon  
See Full Table

Brian R. Mueller Buying and Selling Activity at BioMarin Pharmaceutical

This chart shows Brian Mueller's buying and selling at BioMarin Pharmaceutical by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

BioMarin Pharmaceutical Company Overview

BioMarin Pharmaceutical logo
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Read More

Today's Range

Now: $85.00
Low: $84.29
High: $85.62

50 Day Range

MA: $89.78
Low: $82.16
High: $96.94

2 Week Range

Now: $85.00
Low: $70.73
High: $97.76

Volume

32,569 shs

Average Volume

933,363 shs

Market Capitalization

$15.76 billion

P/E Ratio

326.94

Dividend Yield

N/A

Beta

0.32